Amy Tseng is TissueTech’s President and Chief Executive Officer and a member of the company’s Board of Directors. Amy co-founded Bio-Tissue in 1997 and TissueTech in 2001 with the vision of commercializing cryopreserved amniotic membrane as a platform technology for the treatment of ocular surface diseases. Since its inception, Amy has presided over this mission, building Bio-Tissue into the industry leader in this sector and spearheading the founding of Amniox Medical to expand the Company’s technology into other healthcare sectors. She has guided the company through impressive levels of annual growth. Prior to founding Bio-Tissue, Amy spent 10 years with the big five accounting firms, Ernst & Young and Price Waterhouse. Amy holds a Master of Business Administration from the University of Southern California.
Dr. Scheffer C. G. Tseng co-founded TissueTech and Bio-Tissue and is currently Chief Technology Officer for TissueTech. Dr. Tseng is a world-renowned surgeon in ocular surface reconstruction and a widely published physician scientist with more than 300 peer-reviewed clinical and scientific papers. He pioneered limbal stem cell transplantation and developed and commercialized the CryoTek process to preserve the natural therapeutic properties of amniotic membrane. His research focus for the past 30 years has been to identify the active biological components of human placental tissues, to develop alternative products to deliver their therapeutic properties, and to expand their clinical applications. Dr. Tseng holds a medical degree from National Taiwan University and a Doctorate in Experimental Pathology from the University of California. He completed his residency in ophthalmology at the Wilmer Eye Institute at Johns Hopkins, and his fellowship in cornea and external diseases at Massachusetts Eye and Ear Infirmary. Prior to co-founding TissueTech, Dr. Tseng was a Chair Professor at Bascom Palmer Eye Institute, University of Miami Miller School of Medicine.
Bob has nearly 30 years of experience leading early-stage companies and Fortune 500 business units within the medical technology sector. He is a strong and passionate leader who has a track record of leading several companies through explosive growth. He most recently served as President and CEO of Entellus Medical, Inc, which was acquired by Stryker in 2018, and previously was the President and Chief Executive Officer of TYRX, Inc, which was acquired by Medtronic in 2014. Prior to joining TYRX, Bob held several leadership positions in commercial operations, business development, international sales and marketing, operations and general management for Medtronic, Instromedix/Life Watch, IVAC/Alaris Medical, Eli Lilly, and General Electric. In 2018, he was recognized as a finalist in the Ernst & Young Entrepreneur of the Year and the YPO Global Innovation Award. Bob joined EW Healthcare in May 2019 as Operating Partner. He currently serves as a Director on the Board of AtriCure, in addition to serving on our Board. Bob previously served as a Director on the Boards of Cardiva Medical, Hyperbranch and Novadaq, all of which were acquired.
Devin Buckley joined TissueTech in 2013 with more than 12 years of experience in the life sciences industry. Prior to this, Devin was the Senior Vice President and General Counsel at Stiefel Laboratories, Inc., where he helped build what became the world’s largest dermatology company. Devin previously held positions with United Technologies, United Technologies/Pratt & Whitney, Day, Berry & Howard and Our Kids of Miami-Dade. Devin holds a Bachelor’s Degree from Yale University and a Juris Doctor from Georgetown University.
Michael Cornelius joined TissueTech as Chief Financial Officer in 2014 with more than 25 years of experience in public accounting and public and private corporations. Mr. Cornelius was previously with Stiefel Laboratories, serving as its Chief Financial Officer. Stiefel Laboratories was the largest privately-held dermatology company in the world, before it was acquired by GlaxoSmithKline in 2009. Mike began his career with the international accounting and consulting firm, Grant Thornton, where he specialized in US and International tax planning and also held senior level finance positions with IVAX Corporation and Sunglass Hut International. Mike holds a Bachelor of Science in Business Administration from Indiana University of Pennsylvania and is a Certified Public Accountant.
Tom Williamson is a top producing commercial executive with both large company and start-up experience. Under Tom’s leadership, the Stryker Interventional Spine sales team became a revenue growth leader and established a strong foothold in the competitive vertebral compression fracture market. He then joined Entellus Medical where his last role was VP, Commercial Operations. He helped Entellus grow to over $100M in sales and was integral in their acquisition of Spirox and the final exit of Entellus to Stryker for $662M. Tom holds a Bachelor of Science degree in Chemical Engineering from Louisiana State University and has completed extensive leadership training at Harvard University.